Delving into the Latest Updates on Azithromycin with Synapse

Overview

Basic Info

SummaryAzithromycin, a small molecule drug, works by targeting the 50S subunit of the bacterial ribosome and disrupting protein synthesis, ultimately leading to bacterial death. This drug falls under the class of macrolide antibiotics and is commonly used to treat a diverse range of bacterial infections, such as respiratory tract infections, skin and soft tissue infections, and sexually transmitted infections. It is also used as a prophylactic treatment for certain opportunistic infections in HIV patients. Azithromycin gained FDA approval in 1991, representing a significant breakthrough in the field of antibiotic development. With its broad-spectrum activity against a wide range of bacterial species, Azithromycin is a valuable tool for healthcare providers in managing bacterial infections. However, the overuse or misuse of antibiotics such as Azithromycin can lead to the emergence of antibiotic-resistant bacteria. Therefore, healthcare providers must exercise caution and prudence when prescribing Azithromycin to prevent the development of antibiotic resistance. Overall, Azithromycin is a potent antibiotic that plays a crucial role in the treatment of bacterial infections.

Drug Type

Small molecule drug

Synonyms

Azithromycin (INN), Azithromycin Dihydrate, Azithromycin Hydrate

+ [27]

Target

50S subunit

Mechanism

50S subunit inhibitors(50S ribosomal subunit inhibitors)

Therapeutic Areas

Infectious DiseasesEye DiseasesHemic and Lymphatic Diseases+ [6]

Active Indication

Genital infectionLower Respiratory Tract InfectionsOtitis Media+ [34]

Inactive Indication

Acne VulgarisAcquired Immunodeficiency SyndromeAcute bacterial sinusitis+ [18]

Originator Organization

Pfizer Inc.

Active Organization

Shinpoong Pharmaceutical Co., Ltd.

Pfizer Australia Pty Ltd.

Pfizer Japan, Inc.

+ [5]

Inactive Organization

PF Prism CVTeva Parenteral Medicines, Inc.Cosci MED-TECH Co., Ltd.

+ [4]

Drug Highest PhaseApproved

First Approval Date

US (01 Nov 1991),

Infectious Diseases

RegulationPriority Review (CN), Orphan Drug (JP), Orphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC38H72N2O12

InChIKeyMQTOSJVFKKJCRP-BICOPXKESA-N

CAS Registry83905-01-5

PLATIPUS is an adaptive platform trial aimed at improving the health of infants born preterm (before 37 weeks' gestation). PLATIPUS will compare how different treatments and care provided to pregnant women and people at risk of preterm birth and infants born preterm affect infant health.
The main questions PLATIPUS aims to answer are:
1. What effect/s do different treatments/care provided to pregnant women and people at risk of preterm birth have on the health of their infants? (Pregnancy domains)
2. What effect/s do different treatments/care given to infants born preterm have on their health ? (Neonatal domains).
This registration record relates to the PLATIPUS Core (or 'master') protocol which provides guidance for the overall running of the trial. Additional appendices will outline the aims, questions, treatments, and activities for each separate research question (domain). Each Domain-Specific Appendix will be registered separately on ClinicalTrials.gov and will link to this record.

Start Date01 Feb 2025

Sponsor / Collaborator

University of Melbourne

[+10]

TCTR20220228003 / Not yet recruitingPhase 1

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Azithromycin 200 mg/5 ml Powder for Oral Suspension and Reference Product (ZITHROMAXTM) in Healthy Thai Volunteers under Fasting Conditions

Start Date20 Jan 2025

Sponsor / Collaborator

International Bio Research

NCT06715150 / Not yet recruitingPhase 4

NON-SURGICAL TREATMENT of PERI-IMPLANTITIS with or WITHOUT SYSTEMIC AZITHROMYCIN: a RANDOMIZED CLINICAL TRIAL in HUMANS

The primary objective of this study is to evaluate the change in probing depth in patients with peri-implantitis, assessing the influence of systemic antibiotic (azithromycin) adjunctive to non-surgical treatment at 12 months. The secondary objective is to assess clinical, radiographic, microbiological, and systemic changes at 3, 6, and 12 months.
This study is designed as a placebo-controlled, randomized, triple-blind clinical trial in subjects diagnosed with peri-implantitis.
The treatment will consist of debridement of the implant surface and curettage of the pocket epithelium. The control group will receive placebo (1 placebo tablet per day for 3 days), and the test group will receive systemic azithromycin 500 mg per day for 3 days (1 tablet of 500 mg azithromycin per day for 3 days).

Start Date10 Jan 2025

Sponsor / Collaborator

University of Santiago de Compostela

100 Clinical Results associated with Azithromycin

Login to view more data

100 Translational Medicine associated with Azithromycin

Login to view more data

100 Patents (Medical) associated with Azithromycin

Login to view more data

11,428

Literatures (Medical) associated with Azithromycin

01 Dec 2025·JOURNAL OF CLINICAL IMMUNOLOGY

Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency

Article

Author: Pandrowala, Ambreen ; Mishra-Sopori, Varsha ; Bodhanwala, Minnie ; Khan, Sanaa ; Chandane, Parmarth ; Hiwarkar, Prashant ; Khosla, Indu ; Kataria, Darshan ; Sehgal, Kunal ; Prabhudesai, Pralhad

Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli. The replacement of defective pulmonary alveolar macrophages can be achieved with allogeneic hematopoietic stem cell transplantation. However, previous reports highlight undesirable pulmonary outcomes associated with this therapeutic approach. We report a 4-year-old developmentally normal girl born of second-degree consanguineous marriage diagnosed with severe form of CSFRα-deficient PAP. She required recurrent whole lung lavage and hence was treated with allogeneic hematopoietic stem cell transplantation. A reduced toxicity treosulfan-based myeloablative regimen with alemtuzumab serotherapy was used for conditioning. Ciclosporin, mycophenolate mofetil and FAM (fluticasone inhaler, azithromycin, montelukast) were used to prevent graft-versus-host disease and immune-related complications of lung. Her post-transplant course was uneventful with full donor chimerism and complete resolution of symptoms. We demonstrate for the first time in a case of severe CSF2Rα-deficient PAP, the successful use of hematopoietic stem cell transplantation as a primary curative treatment, restoring normal lungs both anatomically and functionally. The case report provides evidence for considering allogeneic hematopoietic stem cell transplant in severe forms of CSF2R-deficient PAP.

01 Feb 2025·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Impact of doxycycline discharge kits on appropriate treatment of sexually transmitted infections among patients in the ED

Article

Author: Thiemann, Pauline ; Shreffler, Jacob ; Loudermilk, Carly ; Senn, Joshua

BACKGROUND:

Chlamydia trachomatis is the most prevalent, reportable sexually transmitted infection (STI) in the United States. In 2021, the Centers for Disease Control and Prevention (CDC) updated treatment recommendations from a single azithromycin 1000 mg dose to doxycycline 100 mg twice daily for seven days for the treatment of chlamydia infections. In response to changes in treatment recommendations and addressing patient barriers to treatment, pharmacists at an urban, academic medical center collaborated with the state health department to create doxycycline kits dispensed upon emergency department (ED) discharge.

OBJECTIVE:

To evaluate if ED doxycycline discharge kits improve appropriate and timely treatment of chlamydia.

METHODS:

This was a single center, retrospective, chart review study of adult patients with a positive chlamydia test while seen in the ED between September 1, 2021 and September 30, 2023. Patients with a listed allergy to doxycycline and those who were incarcerated and/or pregnant were excluded. The primary outcome was appropriate, guideline recommended chlamydia treatment before and after doxycycline discharge kit implementation. Secondary outcomes included rate of ED return visits within 90 days for STI-related complaints, time to treatment in those who received a prescription for doxycycline versus doxycycline kit, and rate of doxycycline initiation via emergency medicine (EM) pharmacist culture call-back list.

RESULTS:

A total of 170 patients were enrolled in the study, 72 patients in the pre-kit group and 98 patients in the post-kit group. Significantly more patients received appropriate treatment in the post kit group (pre-kit (45.8 %) vs post-kit (69.1 %); CI 95 % 2.63 (1.4-5.0); p = 0.002). Time to definitive treatment was significantly shorter in the post-kit group (22.7 h pre-kit vs 1.3 h post-kit; p < 0.001).

CONCLUSIONS:

Doxycycline discharge kits significantly increased guideline-directed treatment and decreased time-to-treatment for chlamydia in the ED population at an urban academic medical center.

01 Feb 2025·ENVIRONMENTAL POLLUTION

Ten years of monitoring pharmaceuticals and pesticides in the aquatic environment nearby a solid-waste treatment plant: Historical data, trends and risk assessment

Article

Author: Albarrán, Fernando ; Rico, Andreu ; Hernández, Félix ; Simarro-Gimeno, Claudia ; Pitarch, Elena

The emission of contaminants of emerging concern (CECs) from wastewater treatment plants has been extensively studied; however, less attention has been paid to municipal solid waste treatment plants (MSWTPs), which can also be a potential source for CECs into surface water (SW) and groundwater (GW) ecosystems. In this work, the environmental impact of a MSWTP located in the province of Castelló, Spain, was studied along a period of ten years (from 2012 to 2022). A total of 173 water samples (including SW and GW) collected from the surrounding of this plant were monitored for 93 compounds (pharmaceuticals and pesticides) by using liquid chromatography coupled to tandem mass spectrometry with triple quadrupole. This study reveals the presence of several pharmaceuticals (e.g. primidone, gabapentin, azithromycin, clarithromycin, tramadol), particularly in GW samples collected near areas related to composting and storage of biostabilized material. The presence of antibiotic residues in GW raises concerns about the potential development of antimicrobial resistance. In addition, agricultural activities in the study area emerge as potential contributor to GW pollution by pesticides, as the MSWTP is located in an important agricultural area where citrus is the predominant crop. Some compounds that are currently prohibited for agricultural use (e.g. atrazine, simazine, chlorpyrifos) were also found, which highlights the importance of continuing their monitoring to assess their long-term environmental impacts. Several pesticide and pharmaceutical compounds exceeded the threshold values established by the EU groundwater directive. Therefore, a hazard assessment for GW ecosystems and for humans drinking contaminated GW resources was conducted. Our data indicated that some organophosphate insecticides (i.e., chlorpyrifos, carbofuran, pyridaphention) may pose high risks for groundwater crustaceans, while the risks for the human population were considered to be very low.

68

News (Medical) associated with Azithromycin

15 Nov 2024

·www.echemi.com

Pfizer Plans to Sell Hospital Drug Division, 35% of Chinese Market to Change Hands

On November 12, Reuters reported that US pharmaceutical giant Pfizer plans to sell its hospital drugs unit and is currently working with Goldman Sachs to evaluate it. The move means that the products, including antibiotics, steroids and immunoglobulins, will change owners, including the original drug Supraxen, which has a 35 percent market share in China. Pfizer's hospital drugs unit is an asset it acquired after acquiring Hospira for $17 billion in 2015. Less than a decade later, however, Pfizer was willing to put it up for sale, and it is interesting why. It is speculated that the pressure behind this decision may come from investment institutions. The Starboard Value fund made a strategic investment in Pfizer this year, and according to data from the Wall Street Journal, it now holds a $1 billion stake in the company, enough to influence Pfizer's management decisions. Starboard's chief financial officer has repeatedly called on Pfizer to optimize internal capital allocation, liquidate some of its assets and put more money into areas with more potential. Pfizer's hospital pharmaceuticals division includes anti-infective drugs and sterile injections, including well-known antibiotics Supraxen, Sfortol and Zithromax, steroids Medrol and immunoglobulin product Panzyga, and is currently part of its specialty pharmaceuticals business. In 2023, the division contributed billions of dollars in revenue to Pfizer and maintained a 15% growth rate. However, from the perspective of the capital market, such a growth rate still seems to fall short of expectations. Pfizer is widely expected to make further changes to its business segments in the future. Under the significant impact of the Starboard Value fund on Pfizer's strategic layout, Pfizer's core business may also face significant changes, which adds a considerable degree of uncertainty to the company's future development. On November 13, Pfizer's share price was slightly affected, falling nearly 3% at one point.

Acquisition

21 Oct 2024

·www.prnewswire.com

Vietnam Eliminates Trachoma as a Public Health Problem

RTI International congratulates Vietnam in eliminating trachoma – a painful disease impacting the lives of millions of people around the world RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 /PRNewswire/ -- RTI International, a nonprofit research institute and leading international development organization, is pleased to join Vietnam, the World Health Organization (WHO) and the United States Agency for International Development (USAID) in celebrating the elimination of trachoma, a painful disease that can lead to blindness, as a public health problem in Vietnam. Globally, Vietnam is the 21st endemic country to achieve validation of elimination of this neglected tropical disease (NTD). More than 8.3 million people in Vietnam are now free from the risk of trachoma infection. The announcement came at the opening of the WHO Regional Committee for the Western Pacific, being held in Manila, Philippines. "We applaud Vietnam for achieving this incredible goal, which has been over half a century in the making," said Tim J. Gabel , president and CEO at RTI International. "Solving this health problem is an important achievement in improving the human condition and we are proud to be among the partners that assisted in this effort." Trachoma, the leading infectious cause of blindness worldwide, causes eyelids to scar and eyelashes to turn inwards eventually resulting in blindness if untreated. Surgery, antibiotics, facial cleanliness practices and environmental improvements (the SAFE strategy) is the WHO endorsed method for eliminating the disease as a public health problem, including the provision of treatment and care for those at risk for the disease. Trachoma control was first initiated in Vietnam in the 1950s; at that time, the prevalence of active trachoma in some communes was as high as 50-90%. In 1999, the Government of Vietnam established a national trachoma program and began mass treatment campaigns with donated azithromycin. USAID began partnering with Vietnam in 2011 to support their efforts to eliminate trachoma. In recent years, USAID's Act to End Neglected Tropical Diseases | East program, through RTI and partner Fred Hollows Foundation, has supported the government to conduct surveys to monitor prevalence of the disease and ensure care has been provided to those impacted by the disease. These efforts and additional technical assistance have supported the Government of Vietnam to formally document their successes to WHO for validation of trachoma elimination as a public health problem. "This achievement would not have been possible without the commitment of the Government of Vietnam to trachoma elimination," says Lisa Rotondo, program director for USAID's Act to End NTDs | East Program at RTI. "The task now will be for Vietnam to continue surveillance for resurgence and to provide care for those already impacted." Additional partners that have contributed to Vietnam's success include the International Trachoma Initiative, the Australian Department of Foreign Affairs and Trade, Tropical Data, and FHI 360, among others. Over the past 18 years, with support from USAID, RTI has partnered with governments and other countries, including Vietnam, Lao People's Democratic Republic, Cambodia and Nepal, to achieve trachoma elimination as a public health problem. Through the USAID Act | East Program, RTI will continue to support countries in Africa, Asia and the Americas in ending NTDs, such as trachoma. Learn more about RTI's work to control and eliminate NTDs around the globe  Media Contact: Kerry Branon 919-541-7300 [email protected] SOURCE RTI International WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

16 Oct 2024

·www.gsk.com

Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents

16 October 2024 Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials 26 March 2025 assigned as action date for FDA decision Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for the treatment of female adults (≥40 kg) and adolescents (≥12 years, ≥40 kg) with uncomplicated urinary tract infections (uUTIs). The FDA has granted Priority Review for this application and assigned a Prescription Drug User Fee Act (PDUFA) action date of 26 March 2025. Over half of all women are affected by uUTIs in their lifetime1, with approximately 30% suffering from recurrent disease which can cause significant patient burden, including discomfort and restriction of daily activities.2 New treatments are needed as the number of uUTIs caused by drug-resistant bacteria is increasing and can result in higher treatment failure rates.3 Gepotidacin is a late-stage antibiotic in GSK’s growing infectious disease portfolio and could be the first in a new class of oral antibiotics for uUTIs in over 20 years. The NDA is supported by positive results from the pivotal phase III EAGLE-2 and EAGLE-3 trials. In these studies, gepotidacin demonstrated non-inferiority to nitrofurantoin, the current standard of care for uUTI, in female adults (≥40 kg) and adolescents (≥12 years, ≥40 kg) with a confirmed uUTI and a uropathogen susceptible to nitrofurantoin. In EAGLE-3, gepotidacin achieved statistically significant superiority versus nitrofurantoin, demonstrating therapeutic success in 58.5% (162/277) of participants compared to 43.6% (115/264) for nitrofurantoin (treatment difference 14.6%, 95% CI (6.4, 22.8)). In EAGLE-2, gepotidacin demonstrated therapeutic success in 50.6% (162/320) of participants compared to 47.0% (135/287) for nitrofurantoin (treatment difference 4.3%, 95% CI (-3.6, 12.1)). The safety and tolerability profile of gepotidacin in the EAGLE-2 and EAGLE-3 phase III trials was consistent with previous trials of gepotidacin. The most commonly reported adverse events (AEs) in gepotidacin participants were gastrointestinal (GI). Diarrhoea was the most common (16% of participants), followed by nausea (9%). Of the participants who reported GI AEs in the gepotidacin group, the maximum severity were mild (69% Grade 1) and moderate (28% Grade 2). Participants with Grade 3 GI events accounted for 3% of all patients with GI events and occurred in <1% of all participants. There was one drug-related serious adverse event in each treatment arm (gepotidacin and nitrofurantoin) across the two trials. The development of gepotidacin has been funded in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Agreement number HHSO100201300011C and with federal funds awarded by the Defense Threat Reduction Agency under agreement number HDTRA1-07-9-0002. About the EAGLE (Efficacy of Antibacterial Gepotidacin Evaluated) phase III programme The global phase III clinical programme for gepotidacin in adults and adolescents consists of three trials: EAGLE-2 and EAGLE-3 (non-inferiority uUTI trials) compared the efficacy and safety of gepotidacin (1,500mg administered orally twice daily for five days) to nitrofurantoin (100mg administered orally twice daily for five days) with 1531 and 1605 female adults and adolescents with uncomplicated urinary tract infections, respectively. Across both trials, the duration of follow-up for participants was approximately 28 days, and the primary endpoint was the combined clinical and microbiological response at the Test-of-Cure (ToC) visit (days 10-13) in patients with qualifying uropathogens susceptible to nitrofurantoin. EAGLE-1 (non-inferiority urogenital gonorrhoea trial) compared the efficacy and safety of gepotidacin to ceftriaxone plus azithromycin in 628 patients with uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae. About gepotidacin Gepotidacin, discovered by GSK scientists, is an investigational bactericidal, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct binding site, a novel mechanism of action and for most pathogens, provides well-balanced inhibition of two different Type II topoisomerase enzymes. This provides activity against most target uropathogens (such as E. coli and S. saprophyticus), and N. gonorrhoeae, including isolates resistant to current antibiotics. Efficacy and safety in patients have been demonstrated in uUTI and gonorrhoea phase III clinical trials, including those with drug-resistant pathogens. Due to the well-balanced inhibition, gepotidacin target-specific mutations in both enzymes are needed to significantly affect susceptibility to gepotidacin. Therefore, leading to a lower potential for resistance development. GSK in infectious diseases GSK has pioneered innovation in infectious diseases for over 70 years, and the Company’s pipeline of medicines and vaccines is one of the largest and most diverse in the industry, with a goal of developing preventive and therapeutic treatments for multiple disease areas or diseases with high unmet needs globally. GSK’s expertise and capabilities in innovation, access and stewardship position the Company uniquely to help prevent and mitigate the challenge of antimicrobial resistance. In antimicrobials, in addition to gepotidacin, GSK entered into an exclusive licence agreement with Spero Therapeutics, Inc. in September 2022 to add tebipenem HBr, a late-stage antibiotic and potential treatment for complicated urinary tract infections (cUTIs), to the pipeline and are currently enrolling for PIVOT-PO, a phase III trial. In March 2023, GSK announced an exclusive licence agreement with Scynexis for Brexafemme (ibrexafungerp tablets), a first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024. References You might also like

Phase 3License out/inPriority ReviewClinical ResultNDA

100 Deals associated with Azithromycin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07486	Azithromycin	J01FA10 S01AA26	DB00207

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Genital infection	KR	Shinpoong Pharmaceutical Co., Ltd.	28 Jun 2024
Lower Respiratory Tract Infections	KR	Shinpoong Pharmaceutical Co., Ltd.	28 Jun 2024
Otitis Media	KR	Shinpoong Pharmaceutical Co., Ltd.	28 Jun 2024
Skin structures and soft tissue infections	KR	Shinpoong Pharmaceutical Co., Ltd.	28 Jun 2024
Blepharitis	JP	Senju Pharmaceutical Co., Ltd.	18 Jun 2019
Dacryocystitis	JP	Senju Pharmaceutical Co., Ltd.	18 Jun 2019
Hordeolum	JP	Senju Pharmaceutical Co., Ltd.	18 Jun 2019
Conjunctivitis, Bacterial	US	Thea Pharma, Inc.	27 Apr 2007
Acute bacterial sinusitis	US	PF Prism CV	10 Jun 2005
Acute Bronchitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Laryngitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Lung Abscess	JP	Pfizer Japan, Inc.	10 Mar 2000
Lymphadenitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Pericoronitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Periodontitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Pharyngitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Respiratory Tract Infections	JP	Pfizer Japan, Inc.	10 Mar 2000
Sinusitis	JP	Pfizer Japan, Inc.	10 Mar 2000
Skin and skin structure infections	JP	Pfizer Japan, Inc.	10 Mar 2000
Tonsillitis	JP	Pfizer Japan, Inc.	10 Mar 2000

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Inflammation	Phase 3	ML	Pfizer Inc.	15 Oct 2020
Malaria	Phase 3	ML	Pfizer Inc.	15 Oct 2020
COVID-19	Phase 3	US	Pfizer Inc.	22 May 2020
Acne Vulgaris	Phase 3	IT	Pfizer Inc.	01 Oct 2007
Chronic disease of respiratory system	Phase 3	JP	Pfizer Inc.	01 Oct 2006
Asthma	Phase 3	US	Pfizer Inc.	01 Jan 2006
Pneumonia	Phase 3	CA	Pfizer Inc.	01 Apr 2003
Pneumonia	Phase 3	CL	Pfizer Inc.	01 Apr 2003
Pneumonia	Phase 3	IN	Pfizer Inc.	01 Apr 2003
Pneumonia	Phase 3	LT	Pfizer Inc.	01 Apr 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01235546 (Pubmed \| J Matern Fetal Neonatal Med)	Phase 3	Obstetric Labor, Premature	-	Adjunctive Azithromycin Prophylaxis	djcwemrgbh(iubciutdso): OR = 1.06 (95% CI, 0.77 - 1.46), P-Value = 0.42	Positive	01 Dec 2024
				Placebo
NCT03871491 (A-PLUS, CTgov)	Phase 3	Pregnancy Complications, Infectious \| Maternal Death \| Neonatal Sepsis	58,747	Azithromycin (Intervention)	alulbotbgy(zgbkbxgxte) = wgaelwrxob trllbvmdto (kqsbeuvgcz, unycygcczi - qzocymrmvc)	-	24 Oct 2024
				Placebo (Placebo)	alulbotbgy(zgbkbxgxte) = pkfcwpatvg trllbvmdto (kqsbeuvgcz, danmfrknbn - xdfyxgglwo)
NCT05027516 (ResistAZM, CTgov)	Phase 4	Gonorrhea	42	Rocephin (Rocephine®)	dohmxnvbzk(uphxxkzszo) = dxeibppfpq mfegtfouwt (krojmsowpk, wmnlkrudjn - bhwgxohdrw) View more	-	02 Aug 2024
				Azithromycin+Rocephin (Rocephine® + Azithromycin)	wydexzkhzq(bphrlyetfn) = xgjhjrbyqh ryohpdfjut (hbllofjhjs, uusjgczpwe - nxedyopnph) View more
NCT04617626 (Pubmed)	Not Applicable	Trachoma azithromycin	-	1-5 month-olds receiving azithromycin	alojbedtbk(ctxcbuqfub) = kpwkfepnmj mvtwgcxucc (lsgofqllpc ) View more	Positive	10 Jul 2024
NCT04677543 (ARISE, CTgov)	Phase 3	Mycobacterium Infections, Nontuberculous	99	Ethambutol+Azithromycin+ALIS (ALIS + Background Regimen (Azithromycin + Ethambutol))	zrpyeiejyf(cwgkqwfqjj) = ifktvzvkar yytkusyuwi (kgigyyndfo, gkwwerosrr - laybaeqlej) View more	-	28 Jun 2024
				ELC+Ethambutol+Azithromycin (ELC + Background Regimen (Azithromycin + Ethambutol))	zrpyeiejyf(cwgkqwfqjj) = iaukhjnmjz yytkusyuwi (kgigyyndfo, wyfbkcjmxj - snsxdjlpuc) View more
NCT03060473 (TREAT, CTgov)	Phase 3	Preterm Premature Rupture of the Membranes	21	Amoxicillin+Azithromycin+Ampicillin (Azithromycin)	nnrpzozlje(wjdhvnmrxf) = vrxprkksvy zjvtdkbsxp (buklvmmils, nnipqoumti - rnsaopzoxo) View more	-	25 Jun 2024
				Amoxicillin+Ampicillin+Erythromycin (Erythromycin)	nnrpzozlje(wjdhvnmrxf) = ckywckgrol zjvtdkbsxp (buklvmmils, myykfprppg - abvpefegif) View more
ATS2024	Not Applicable	Bronchiectasis	-	Azithromycin 250mg	qicjcmfyga(bwzghhcdys) = vymzyxwvai aipcxrdgpw (nugvehxrbm ) View more	-	19 May 2024
NCT04341727 (WU352, CTgov)	Phase 3	COVID-19 \| Severe Acute Respiratory Syndrome	30	Hydroxychloroquine Sulfate (Hydroxychloroquine Alone)	bwsaqfqdfs(vplmegycfa) = sjminwndtp wvtwmeqgcb (vtexwczibr, eihudnsvaw - puwwotutxg) View more	-	25 Apr 2024
				Hydroxychloroquine Sulfate+Azithromycin (Hydroxychloroquine Plus Azithromycin)	bwsaqfqdfs(vplmegycfa) = ehuuljttaj wvtwmeqgcb (vtexwczibr, pqaoqejmuk - gjcyvcdvuj) View more
NCT03801252 (APPOINT, CTgov)	Early Phase 1	Labor, Induced \| Obesity	186	Cefazolin+Azithromycin (Cefazolin + Azithromycin)	kzinwxcdsk(takcbklody) = aqjrrhwtyf gilvbggogc (gqkeqhczbo, lvwhibyhxn - yxtqckcweu) View more	-	19 Apr 2024
				Placebo (Placebo + Placebo)	kzinwxcdsk(takcbklody) = gfvzgyhrqc gilvbggogc (gqkeqhczbo, opkhofvxhp - svnkxygcwg) View more
NCT03130114 (ABCD, Pubmed \| J Infect Dis) Manual	Phase 3	Diarrhea	6,692	Azithromycin	plwxbrimns(yjwfqzrbjh) = owuzswucgs hbalacncag (guvmyggmka )	Positive	12 Apr 2024
				Placebo	plwxbrimns(yjwfqzrbjh) = dnjpfznerm hbalacncag (guvmyggmka )